Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma

    Research output: Contribution to journalReviewResearchpeer-review

  4. Outcome of an enhanced diagnostic pipeline for patients suspected of inherited thrombocytopenia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A shared somatic translocation involving CUX1 in monozygotic twins as an early driver of AMKL in Down syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Response to: Patient-centred medical education: A proposed definition

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Clara M A de Bruijn
  • Frédéric Millot
  • Meinolf Suttorp
  • Marina Borisevich
  • Paul Brons
  • Birgitte Lausen
  • Eveline S J M de Bont
View graph of relations

This international study aimed to assess the effect of imatinib discontinuation in paediatric patients with chronic myeloid leukaemia (CML) after deep molecular remission (DMR) had been achieved and maintained for at least 2 years. The primary endpoint of this analysis was the molecular relapse-free survival, estimated by the non-parametric Kaplan-Meier method. Major endpoint was the estimated rate of patients without molecular relapse at 6 months. Fourteen patients were enrolled; 4 patients maintained DMR with a follow-up of 24 (two patients), 34 and 66 months, respectively, whereas 10 patients relapsed. All molecular relapses occurred within 6 months (median 3 months, range 1-6) after imatinib discontinuation. The overall probability of maintaining DMR at 6 months was 28·6%. No parameters associated with molecular relapse could be identified. Keeping in mind the rarity of paediatric CML, which contributed to the small size of the cohort, our findings illustrate that imatinib cessation after sustained DMR is successful in only limited numbers of patients, whereas much higher rates are reported in adult patients. Further research is needed to extend the cohort of paediatric CML patients who might achieve treatment-free remission with an ideal prerequisite of predicting the occurrence of molecular relapse l after imatinib cessation.

Original languageEnglish
JournalBritish Journal of Haematology
Volume185
Issue number4
Pages (from-to)718-724
Number of pages7
ISSN0007-1048
DOIs
Publication statusPublished - 2019

ID: 59088082